Lantern Pharma Inc. Annual Report - How They Did This Year

This guide helps you understand how Lantern Pharma performed this year. We will break down their progress, financial health, and what you should watch as an investor.

1. What does this company do?

Lantern Pharma is a "tech-first" biotech company. Instead of traditional trial-and-error, they use their AI platform, RADR®, to analyze over 200 billion data points. They study genomic and drug-sensitivity data to predict which patients will respond to specific cancer drugs. This saves time and money by avoiding the high failure rates common in drug development.

They use a "rescue" strategy. They license drugs that other companies abandoned because they didn't work for the general population. They then use AI to find specific patients who would benefit. By focusing on these "responders," they aim to increase trial success while cutting development costs by 30-50%.

2. Major wins this year

• Pipeline Growth: In 2025, the FDA cleared two new Phase 1b/2 clinical trials for their lead drug, LP-184. One targets solid tumors with DNA damage repair deficiencies. This addresses a lung cancer market worth over $2 billion annually.
• New Tech: They launched withZeta.ai, a generative AI "co-scientist." This tool works with RADR® to automate complex biological data analysis. It aims to cut the time needed to identify drug-biomarker signatures from months to days.
• AI Upgrades: They added over 160 machine learning algorithms to RADR®. A key addition is the blood-brain barrier module. It uses deep learning to predict if a drug can reach the brain, which is vital for treating brain cancer.

3. Financial health: The "Going Concern" warning

Lantern is still in the research phase and has no products for sale. For the year ending December 31, 2024, they had almost no revenue. They reported a loss of about $22.5 million, reflecting their heavy investment in research.

The company has noted "substantial doubt" about their ability to keep operating for the next 12 months without raising more money. They held about $25 million in cash as of their last report. To fund operations, they sell new shares to the public. This creates more shares, which reduces your ownership percentage and can lower the stock price.

4. Key risks

• The "All-or-Nothing" Nature: Since they have no products for sale, their value is speculative and tied to clinical trial success. If a trial for LP-184 or LP-300 fails, the stock price will likely drop significantly.
• Reliance on Third Parties: Lantern is a "virtual" biotech. They outsource manufacturing and clinical trials. If their partners face delays or supply chain issues, Lantern has no internal backup, which could stall their progress.
• Regulatory Hurdles: The FDA requires strict proof of safety and effectiveness. They might demand larger trials, which would require more cash than the company currently has.
• Thin Trading: The stock has low trading volume, making it very volatile. Large sell orders can cause the price to drop sharply because there may not be enough buyers to absorb the trade.

---

Investor Takeaway: Lantern Pharma is a high-risk, high-reward play. Your investment is essentially a bet on their AI platform's ability to successfully navigate clinical trials. Because they rely on selling shares to fund their research, keep a close eye on their cash balance and any announcements regarding new stock offerings, as these will directly impact the value of your holdings.